Akso Health Group (NASDAQ:AHG) Shares Gap Down – Should You Sell?

Akso Health Group Sponsored ADR (NASDAQ:AHG) shares gapped down prior to trading on Monday . The stock had previously closed at $1.51, but opened at $1.43. Akso Health Group shares last traded at $1.5240, with a volume of 173 shares trading hands.

Analysts Set New Price Targets

AHG has been the subject of a number of research analyst reports. Wall Street Zen upgraded Akso Health Group to a “sell” rating in a report on Saturday, May 2nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Akso Health Group in a report on Monday, April 20th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock currently has an average rating of “Sell”.

Akso Health Group Trading Up 0.3%

The stock has a fifty day moving average price of $1.64 and a 200-day moving average price of $1.69.

Institutional Investors Weigh In On Akso Health Group

A hedge fund recently bought a new stake in Akso Health Group stock. SmartHarvest Portfolios LLC bought a new stake in Akso Health Group Sponsored ADR (NASDAQ:AHG) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 16,748 shares of the company’s stock, valued at approximately $27,000. Hedge funds and other institutional investors own 1.21% of the company’s stock.

About Akso Health Group

Akso Health Group operates a social e-commerce mobile platform in China. The company operates Xiaobai Maimai App, which offers food and beverage products, wine, cosmetic products, fashion and apparel, entertainment products, housewares, home appliances, and cost-saving promotions at petrol gas stations. It also offers consultancy and information technology support services; provides health treatment services; sells medical devices; and trades in branded products, as well as promotes products. The company was formerly known as Xiaobai Maimai Inc and changed its name to Akso Health Group in December 2021.